Your First 30 Days on a GLP-1, Week by Week

The first month on a GLP-1 is the most misunderstood stretch of the whole treatment. It is also when most people decide — often on bad information — whether to continue. Here is what the month actually looks like, week by week, and which signals matter.

Before Week 1: Why Your Dose Looks "Too Small"

Every approved GLP-1 regimen starts far below its target dose. Tirzepatide, per the FDA's approval documentation, begins at 2.5 mg weekly and escalates over 4 to 20 weeks; semaglutide follows a similar months-long ladder. The starter dose is not your treatment dose — it exists to let your gastrointestinal system adapt. Two practical implications: do not expect starter-dose results, and do not pressure your clinician to skip steps. The ladder is the safety mechanism.

Weeks 1–2: The Adjustment Window

The first noticeable change for most people is appetite — meals end sooner, snacking impulses quiet down. This is the mechanism working: the medication mimics gut hormones that signal fullness. The same mechanism produces the early side effects, which the FDA lists as nausea, diarrhea, vomiting, and constipation among the most common. Eating smaller meals, slowing down, and staying hydrated are the standard early-week tactics; your program's clinician should be your first message if symptoms feel unmanageable rather than unpleasant.

Weeks 3–4: Routine, Refill, First Data

By weeks three and four, injection day becomes routine and your first refill cycle kicks in — worth confirming the logistics before you run low. On the scale: expect modest movement, not transformation. The trial curves that produced the famous numbers (14.9% average for semaglutide at week 68 in STEP 1; up to 20.9% for tirzepatide at week 72 in SURMOUNT-1) accumulated over more than a year, with the first month spent mostly at sub-therapeutic doses. A few pounds in month one is a normal opening, not a verdict.

What Deserves a Call, Not Patience

Routine side effects are managed with messages and meal tactics. A short list warrants direct clinical contact: severe or persistent abdominal pain (pancreatitis is a flagged risk in FDA labeling), symptoms of gallbladder trouble, signs of dehydration from vomiting or diarrhea, and any allergic reaction. If you become pregnant or plan to, that conversation happens immediately — these medications are not for use in pregnancy.

Set the 30-Day Finish Line Correctly

The honest goal for day 30 is not a target weight. It is: dose schedule kept, side effects managed and communicated, eating pattern adapted, refill logistics working, and a check-in completed. Hit those five and the months where the real results accrue are set up properly. If you are still comparing programs before starting, our weight-loss treatment comparison covers the eligibility, pricing, and support questions worth settling first.